Evidence map›Paper›PMID 21226578›Full record

ArticleThe New England journal of medicine2011

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

Amit V Khera, Marina Cuchel, Margarita de la Llera-Moya, Amrith Rodrigues, Megan F Burke, Kashif Jafri, Benjamin C French, Julie A Phillips, Megan L Mucksavage, Robert L Wilensky and 3 more

Abstract read
In one paragraph

Article in The New England journal of medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 999 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
999citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

999 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

939 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Amit V KheraCardiovascular Institute, University of Pennsylvania, Philadelphia, USA.
Marina Cuchel
Margarita de la Llera-Moya
Amrith Rodrigues
Megan F Burke
Kashif Jafri
Benjamin C French
Julie A Phillips
Megan L Mucksavage
Robert L Wilensky
Emile R Mohler
George H Rothblat
Daniel J Rader

Funding

INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
TISSUE CULTURE CORE LABORATORYP01HL022633 · NHLBI · MCP HAHNEMANN UNIVERSITY · PI ROTHBLAT, GEORGE H · 1985 to 2013
$26.1M
ZDV VS ZDV + DDL VS ZDV + DDL + NVP IN ASYMPTOMATIC HIV PATIENTSM01RR000040 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 1985 to 2006
$21.1M
Oxidative Modifications of Proteins and Fibrinogen in AtherosclerosisP50HL070128 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ISCHIROPOULOS, HARRY · 2002 to 2006
$10.8M
Mechanistic study of CHD risk in subjects with high HDLCK23HL077146 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CUCHEL, MARINA · 2004 to 2008
$662k
Howard Hughes Medical InstituteNCRR NIH HHS M01 RR000040NCRR NIH HHS M01 RR00040NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1-RR-024134NHLBI NIH HHS HL22633NHLBI NIH HHS K23 HL077146NHLBI NIH HHS P01 HL022633NHLBI NIH HHS P50 HL070128NHLBI NIH HHS P50 HL70128
6 · The paper itself

Abstract

backgroundHigh-density lipoprotein (HDL) may provide cardiovascular protection by promoting reverse cholesterol transport from macrophages. We hypothesized that the capacity of HDL to accept cholesterol from macrophages would serve as a predictor of atherosclerotic burden.

methodsWe measured cholesterol efflux capacity in 203 healthy volunteers who underwent assessment of carotid artery intima-media thickness, 442 patients with angiographically confirmed coronary artery disease, and 351 patients without such angiographically confirmed disease. We quantified efflux capacity by using a validated ex vivo system that involved incubation of macrophages with apolipoprotein B-depleted serum from the study participants.

resultsThe levels of HDL cholesterol and apolipoprotein A-I were significant determinants of cholesterol efflux capacity but accounted for less than 40% of the observed variation. An inverse relationship was noted between efflux capacity and carotid intima-media thickness both before and after adjustment for the HDL cholesterol level. Furthermore, efflux capacity was a strong inverse predictor of coronary disease status (adjusted odds ratio for coronary disease per 1-SD increase in efflux capacity, 0.70; 95% confidence interval [CI], 0.59 to 0.83; P<0.001). This relationship was attenuated, but remained significant, after additional adjustment for the HDL cholesterol level (odds ratio per 1-SD increase, 0.75; 95% CI, 0.63 to 0.90; P=0.002) or apolipoprotein A-I level (odds ratio per 1-SD increase, 0.74; 95% CI, 0.61 to 0.89; P=0.002). Additional studies showed enhanced efflux capacity in patients with the metabolic syndrome and low HDL cholesterol levels who were treated with pioglitazone, but not in patients with hypercholesterolemia who were treated with statins.

conclusionsCholesterol efflux capacity from macrophages, a metric of HDL function, has a strong inverse association with both carotid intima-media thickness and the likelihood of angiographic coronary artery disease, independently of the HDL cholesterol level. (Funded by the National Heart, Lung, and Blood Institute and others.).

Indexed as

AgedBiological TransportCarotid ArteriesCase-Control StudiesCholesterolCoronary Artery DiseaseFoam CellsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsLipoproteins, HDLLogistic ModelsMiddle AgedPioglitazoneRadiographySmokingCholesterolHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsLipoproteins, HDLPioglitazoneThiazolidinediones

Identifiers

PMID21226578
PMCPMC3030449

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.